Simon holds a BCom from the University of Canterbury and has spent more than 25 years in the global investment management industry having held senior Investment and Business Leadership roles in some of the world’s pre-eminent investment management firms.

His global perspective was honed through his years as a senior business leader and investor while working in London, Hong Kong and Singapore managing businesses, portfolios and teams of investors managing money on behalf of institutional investors from both the private as well as public sectors. Simon was a Managing Director at Merrill Lynch Investment Managers and COO of their Asian Business. He was Chief Investment Officer at Lion Global Investors, and prior to returning to New Zealand he was Head of Asia for AXA Investment Managers.

As an investor, Simon has had responsibility for the analysis and investment in listed equities, fixed income and has also had experience in the commercialisation of intellectual property and early-stage investment. While an analyst and portfolio manager Simon developed a keen interest in the global healthcare industry and has maintained that interest and knowledge base throughout his career.

Having returned to New Zealand in 2015, Simon has been appointed to several Boards and is currently the Chair of Queenstown Airport and is on the board of a number of other companies and foundations covering sectors of significance in the New Zealand economy.

Anatole is the co-founder of Artemis Capital, a private equity investment firm based in Auckland. He graduated from the University of Auckland with an MCom (Hons) in Finance and Economics. Following that he spent eight years with Air New Zealand (and later the merged entity with Ansett Australia) holding senior positions in Pricing, Revenue Management and Systems implementation. He holds directorships in numerous private companies and has significant knowledge of financial capital markets. As a long standing director of PEB and investor in numerous medical and tech companies, Anatole has an a detailed knowledge of the medical sector and future trends. In particular human sciences and disruptive technologies.

Sarah has over 25 years’ experience in corporate finance and capital markets. Her career includes roles with PwC in New Zealand and HSBC Investment Bank in London, as well as subsequent experience in investment management. Sarah co-founded Even Capital, a venture capital firm investing exclusively in female entrepreneurs across New Zealand and Australia.

She is an experienced early-stage investor with a particular focus on healthcare. She has built deep knowledge of how to move science from the lab to commercial application, including the investment and commercialisation pathways needed to scale successfully.

Sarah has broad governance experience, having held a number of board roles in different industries over the past 12 years. She is currently a member of the board of the Government Superannuation Fund Authority, National Provident Fund and Orbis Diagnostics. Sarah holds a Master of Arts (Honours) in Economics from the University of Edinburgh and is a member of the New Zealand Institute of Directors and Chapter Zero New Zealand.

Bryan is an internationally recognised cancer researcher and research administrator, with significant business experience. He has held a number of governance roles, including with a NASDAQ listed biotech company. Presently, he serves on boards of two Australian and one American privately held biotechnology companies. He is also a co-founder of an American biotechnology company. Bryan was Director and CEO of the Hudson Institute of Medical Research. He is currently Emeritus Director and Distinguished Scientist at the Hudson Institute in Melbourne. He has a BSc (Hons) and PhD in Microbiology from the University of Otago.

Anna is an experienced leader with more than 25 years’ global executive and board experience across healthcare, biotechnology and regulated scientific sectors. She has a strong track record guiding organisations through growth, commercial transformation and complex regulatory environments, underpinned by deep commercial and scientific literacy.

Her executive career spans senior leadership roles across Asia Pacific and Europe, culminating in her appointment as New Zealand General Manager for GlaxoSmithKline.

Anna has held a number of significant governance roles including Chair of TAB NZ, Chair of Global Women NZ, Director of Medicines New Zealand, and Vice Chair of Shooting Star Children’s Hospices in London. She is currently Chair of Rua Bioscience.

Tony brings over 30 years experience in business and 22 years healthcare experience. Tony was CFO at medical device company Fisher & Paykel Healthcare from the time of separation from Fisher & Paykel Appliances in 2001 until retiring from full-time employment in 2018. Prior to Fisher & Paykel Healthcare Tony worked for PriceWaterhouse and Arnott's Biscuits in finance roles. Tony is also a board member of listed company Rua Bioscience and holds a number of directorships in private companies, all in MedTech. Tony holds a BCom from the University of Otago and is a Chartered Accountant and a member of the New Zealand Institute of Directors and INFINZ.